Belimumab for systemic lupus erythematosus (SLE) has demonstrated a stable safety profile over 8 years of follow-up, with no new safety signal and minimal organ damage progression, according to data from an extension study involving non-American patients who completed the phase III BLISS*-52 or BLISS-76 trials.
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Adults with moderate-to-severe rheumatoid arthritis (RA) with inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARDs) may benefit from treatment with the selective Janus kinase (JAK)-1 inhibitor filgotinib, the phase III FINCH 2* trial shows.
Progression of skin fibrosis* within 1 year is associated with long-term deterioration in lung function and worse survival in individuals with diffuse cutaneous systemic sclerosis (dcSSc), according to data from the EUSTAR** cohort.
A transitional care rehabilitation programme incorporating occupational therapy and cognitive behavioural coaching informed by sensor monitoring effectively improves daily functioning at 6 months as compared with usual care among older adults recovering from hip fracture, as shown in a study.
Privacy and transparency are among the core points to consider when utilizing big data in rheumatic and musculoskeletal disorders (RMDs), according to the first EULAR-endorsed recommendations for use of big datasets in research.
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Switching to a monotherapy treatment with the oral JAK1*-selective inhibitor upadacitinib a monotherapy ofsignificantly improves clinical and functional outcomes compared with continuing the csDMARD** methotrexate in patients with active rheumatoid arthritis (RA) who have an inadequate response to methotrexate, according to the SELECT-MONOTHERAPY study.
The antinerve growth factor fasinumab delivers significant analgesic effects in patients experiencing moderate-to-severe pain from osteoarthritis, including those benefitting little from a previous analgesic, according to the results of a phase IIB/III trial.
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.